Frankfurt - Delayed Quote EUR

Bristol-Myers Squibb Company (BRM.F)

Compare
54.23
-0.66
(-1.20%)
At close: January 10 at 4:16:03 PM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
47,435,000.00
45,006,000.00
46,159,000.00
46,385,000.00
42,518,000.00
Cost of Revenue
11,901,000.00
10,693,000.00
10,137,000.00
9,940,000.00
11,773,000.00
Gross Profit
35,534,000.00
34,313,000.00
36,022,000.00
36,445,000.00
30,745,000.00
Operating Expense
28,254,000.00
26,118,000.00
26,918,000.00
27,908,000.00
28,568,000.00
Operating Income
7,280,000.00
8,195,000.00
9,104,000.00
8,537,000.00
2,177,000.00
Net Non Operating Interest Income Expense
-1,767,000.00
-1,166,000.00
-1,232,000.00
-1,334,000.00
-1,420,000.00
Other Income Expense
-12,393,000.00
1,411,000.00
-159,000.00
895,000.00
-7,628,000.00
Pretax Income
-6,880,000.00
8,440,000.00
7,713,000.00
8,098,000.00
-6,871,000.00
Tax Provision
367,000.00
400,000.00
1,368,000.00
1,084,000.00
2,124,000.00
Net Income Common Stockholders
-7,258,000.00
8,025,000.00
6,327,000.00
6,994,000.00
-9,015,000.00
Diluted NI Available to Com Stockholders
-7,258,000.00
8,025,000.00
6,327,000.00
6,994,000.00
-9,015,000.00
Basic EPS
-3.58
3.88
2.97
3.25
-3.99
Diluted EPS
-3.58
3.86
2.95
3.12
-3.99
Basic Average Shares
2,026,250.00
2,069,000.00
2,130,000.00
2,153,000.00
2,258,000.00
Diluted Average Shares
2,027,750.00
2,078,000.00
2,146,000.00
2,245,000.00
2,258,000.00
Total Expenses
40,155,000.00
36,811,000.00
37,055,000.00
37,848,000.00
40,341,000.00
Net Income from Continuing & Discontinued Operation
-7,258,000.00
8,025,000.00
6,327,000.00
6,994,000.00
-9,015,000.00
Normalized Income
3,256,900.00
7,997,363.00
7,439,696.00
7,213,999.51
-2,188,770.00
Interest Expense
1,767,000.00
1,166,000.00
1,232,000.00
1,334,000.00
1,420,000.00
Net Interest Income
-1,767,000.00
-1,166,000.00
-1,232,000.00
-1,334,000.00
-1,420,000.00
EBIT
-5,113,000.00
9,606,000.00
8,945,000.00
9,432,000.00
-5,451,000.00
EBITDA
5,071,000.00
19,366,000.00
19,221,000.00
20,118,000.00
4,929,000.00
Reconciled Cost of Revenue
11,174,000.00
9,980,000.00
9,456,000.00
9,277,000.00
11,081,000.00
Reconciled Depreciation
10,184,000.00
9,760,000.00
10,276,000.00
10,686,000.00
10,380,000.00
Net Income from Continuing Operation Net Minority Interest
-7,258,000.00
8,025,000.00
6,327,000.00
6,994,000.00
-9,015,000.00
Total Unusual Items Excluding Goodwill
-13,310,000.00
29,000.00
-1,352,000.00
-254,000.00
-9,351,000.00
Total Unusual Items
-13,310,000.00
29,000.00
-1,352,000.00
-254,000.00
-9,351,000.00
Normalized EBITDA
18,381,000.00
19,337,000.00
20,573,000.00
20,372,000.00
14,280,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-2,795,100.00
1,363.00
-239,304.00
-34,000.49
-2,524,770.00
12/31/2020 - 1/3/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

JNJ.CL Johnson & Johnson
619,740.00
+1.21%
 
0R34.IL Johnson & Johnson
143.00
+0.49%
 
LILY34.SA Eli Lilly and Company
162.20
+1.99%
 
GRF.MC Grifols, S.A.
9.06
-0.57%
 
NOV.DE Novo Nordisk A/S
84.60
-0.31%
 
NONOF Novo Nordisk A/S
85.80
0.00%
 
SNY Sanofi
48.73
-1.02%
 
MRK Merck & Co., Inc.
99.25
-0.60%
 
AZN AstraZeneca PLC
67.01
+0.65%
 
PFE Pfizer Inc.
26.72
-0.52%